ADC Therapeutics is seeking review from the FDA regarding the sBLA submission for its product, ZYNLONTA.
2 reports, 1 independent
Updated Jun 30
Gone quiet
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
ADC Therapeutics is seeking review from the FDA regarding the sBLA submission for its product, ZYNLONTA.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
ADC Therapeutics
company in Épalinges, Switzerland
Nothing else this week.
- FDA
Related events
- ADC Therapeutics is seeking accelerated approval from the FDA for its Zynlonta therapy.
- Mesoblast is seeking FDA review of the BLA for its product rexlemestrocel-L.
- FDA granted Priority Review for the BLA submission of the SkinTE product.
- Amylyx Pharmaceuticals is seeking FDA approval for a new drug treatment.
- The FDA is reviewing a drug approval application for a condition involving the company GAD.